Related Experiment Video
Updated: Sep 12, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.1K
Protein targets & therapeutics in psoriasis: toward personalization
Mohammad Abuzar Shaikh1, Ziyaul Haque1, Anzarul Haque2
1Anjuman-I-Islam's Kalsekar Technical Campus School of Pharmacy, Affiliated to University of Mumbai, New Panvel, 410206, Maharashtra, India.
International Immunopharmacology
|August 10, 2025
Summary
This review explores protein targets for psoriasis treatment, including inflammation regulators, keratinocyte growth factors, and immune modulators. Targeting these proteins may lead to personalized therapies for the chronic skin condition affecting millions globally.
Area of Science:
- Dermatology and Immunology
- Molecular Biology
- Structural Biology
Background:
- Psoriasis is a chronic, immune-mediated skin disease affecting over 125 million worldwide.
- Characterized by plaques, itching, and scaling, it's linked to comorbidities like psoriatic arthritis and cardiovascular disease.
- Pathogenesis involves genetic, environmental, and immune factors, leading to chronic inflammation and keratinocyte hyperproliferation.
Purpose of the Study:
- To review the treatment potential of key protein targets implicated in psoriasis.
- To explore the structural biology of these proteins for drug-binding site insights.
- To highlight proteins crucial for developing personalized psoriasis treatment strategies.
Main Methods:
- Literature review of proteins involved in psoriasis pathogenesis.
- Analysis of protein functions in inflammatory cascades and keratinocyte biology.
- Examination of structural data from the Protein Data Bank (PDB) for molecular interactions.
Main Results:
- Identified key proteins: transcriptional regulators (ACKR2, NFKBIZ, TNIP1), keratinocyte factors (PK2, KPNA2), kynurenine pathway enzymes (KYNU, IDO), inflammatory mediators (CXCL10, CYR61), and antimicrobial peptides (LL37, S100A15).
- These proteins are significantly upregulated in psoriatic lesions, maintaining chronic inflammation.
- Structural biology insights reveal potential drug-binding sites for molecular targeting.
Conclusions:
- Proteins like LL37, TNIP1, and RORγt show unique roles in psoriatic pathology, suggesting personalized treatment potential.
- Combining molecular targeting with biologics offers a promising avenue for individualized psoriasis therapies.
- These identified proteins serve as potential biomarkers and therapeutic targets for future interventions.
More Related Videos
Related Concept Videos
01:26Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
01:22iPS Cell Differentiation
2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
01:24Principles of Drug Action
6.6K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.6K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
254
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
254
01:21EPS and iPS Cells in Disease Research
2.9K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.9K